Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1947 1
1950 2
1951 1
1953 2
1955 1
1956 2
1957 4
1958 1
1959 1
1960 15
1961 7
1962 9
1963 9
1964 7
1965 15
1966 13
1967 11
1968 10
1969 11
1970 12
1971 10
1972 8
1973 25
1974 14
1975 24
1976 20
1977 18
1978 19
1979 21
1980 27
1981 25
1982 24
1983 22
1984 18
1985 20
1986 29
1987 30
1988 62
1989 71
1990 76
1991 70
1992 96
1993 83
1994 82
1995 80
1996 83
1997 104
1998 101
1999 124
2000 149
2001 145
2002 158
2003 142
2004 182
2005 194
2006 180
2007 219
2008 224
2009 238
2010 265
2011 266
2012 289
2013 341
2014 369
2015 430
2016 514
2017 554
2018 616
2019 667
2020 809
2021 934
2022 1051
2023 944
2024 973
2025 761
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

11,683 results

Results by year

Filters applied: . Clear all
Page 1
The Role of ICS-Containing Rescue Therapy Versus SABA Alone in Asthma Management Today.
Krings JG, Beasley R. Krings JG, et al. J Allergy Clin Immunol Pract. 2024 Apr;12(4):870-879. doi: 10.1016/j.jaip.2024.01.011. Epub 2024 Jan 17. J Allergy Clin Immunol Pract. 2024. PMID: 38237858 Free PMC article. Review.
These recommendations are based on the risks of SABA monotherapy, the evidence that ICS-formoterol reliever therapy markedly decreases the occurrence of severe asthma exacerbations compared with SABA reliever therapy alone, and because ICS-formoterol reliever therap …
These recommendations are based on the risks of SABA monotherapy, the evidence that ICS-formoterol reliever therapy markedly decrease …
Expert Consensus on SABA Use for Asthma Clinical Decision-Making: A Delphi Approach.
Lugogo N, O'Connor M, George M, Merchant R, Bensch G, Portnoy J, Oppenheimer J, Castro M. Lugogo N, et al. Curr Allergy Asthma Rep. 2023 Nov;23(11):621-634. doi: 10.1007/s11882-023-01111-z. Epub 2023 Nov 22. Curr Allergy Asthma Rep. 2023. PMID: 37991672 Free PMC article. Review.
RECENT FINDINGS: In Phase 1 (n = 100 clinicians), 12% routinely provided patients with 4 SABA prescriptions/year, 73% solicited SABA use frequency at every patient visit, and 21% did not consult asthma guidelines/expert reports. Phase 3 experts (n = 8) reached conse …
RECENT FINDINGS: In Phase 1 (n = 100 clinicians), 12% routinely provided patients with 4 SABA prescriptions/year, 73% solicited SA …
Safety of SABA Monotherapy in Asthma Management: a Systematic Review and Meta-analysis.
Sriprasart T, Waterer G, Garcia G, Rubin A, Andrade MAL, Roguska A, Phansalkar A, Fulmali S, Martin A, Mittal L, Aggarwal B, Levy G. Sriprasart T, et al. Adv Ther. 2023 Jan;40(1):133-158. doi: 10.1007/s12325-022-02356-2. Epub 2022 Nov 8. Adv Ther. 2023. PMID: 36348141 Free PMC article.
A random-effects model estimated rates of mortality, serious AEs (SAEs), and discontinuation due to AEs (DAEs) for as-needed and fixed-dose SABA treatment groups. ICS monotherapy and SABA therapy were compared using a fixed-effects model. ...SAE risk was comparable …
A random-effects model estimated rates of mortality, serious AEs (SAEs), and discontinuation due to AEs (DAEs) for as-needed and fixed-dose …
Landscape of short-acting beta-agonists (SABA) overuse in Europe.
de Las Vecillas L, Quirce S. de Las Vecillas L, et al. Clin Exp Allergy. 2023 Feb;53(2):132-144. doi: 10.1111/cea.14250. Epub 2022 Dec 5. Clin Exp Allergy. 2023. PMID: 36468654 Review.
Almost a third of European patients with asthma, at all severity levels, overuse SABA. Guidelines recommend close monitoring of patients who overuse SABA and avoiding over-reliance on SABA monotherapy. ...Changes in physician and patient behaviours towards …
Almost a third of European patients with asthma, at all severity levels, overuse SABA. Guidelines recommend close monitoring of patie …
Effective Asthma Management: Is It Time to Let the AIR out of SABA?
Kaplan A, Mitchell PD, Cave AJ, Gagnon R, Foran V, Ellis AK. Kaplan A, et al. J Clin Med. 2020 Mar 27;9(4):921. doi: 10.3390/jcm9040921. J Clin Med. 2020. PMID: 32230875 Free PMC article. Review.
For years, standard asthma treatment has included short acting beta agonists (SABA), including as monotherapy in patients with mild asthma symptoms. In the Global Initiative for Asthma 2019 strategy for the management of asthma, the authors recommended a significant depart …
For years, standard asthma treatment has included short acting beta agonists (SABA), including as monotherapy in patients with mild a …
Helicobacter pylori BabA-SabA Key Roles in the Adherence Phase: The Synergic Mechanism for Successful Colonization and Disease Development.
Doohan D, Rezkitha YAA, Waskito LA, Yamaoka Y, Miftahussurur M. Doohan D, et al. Toxins (Basel). 2021 Jul 13;13(7):485. doi: 10.3390/toxins13070485. Toxins (Basel). 2021. PMID: 34357957 Free PMC article. Review.
The blood group antigen-binding adhesion (BabA) and sialic acid-binding adherence (SabA) are two H. pylori outer membrane proteins able to interact with antigens in the gastroduodenal tract. ...The adherence mechanisms of BabA and SabA allow H. pylori to anchor in t …
The blood group antigen-binding adhesion (BabA) and sialic acid-binding adherence (SabA) are two H. pylori outer membrane proteins ab …
SABA use as an indicator for asthma exacerbation risk: an observational cohort study (SABINA Canada).
Noorduyn SG, Qian C, Johnston KM, Soliman M, Talukdar M, Walker BL, Hernandez P, Penz E. Noorduyn SG, et al. ERJ Open Res. 2022 Sep 26;8(3):00140-2022. doi: 10.1183/23120541.00140-2022. eCollection 2022 Jul. ERJ Open Res. 2022. PMID: 36171990 Free PMC article.
BACKGROUND: Patients with asthma use short-acting beta-agonists (SABA) to relieve symptoms but SABA alone does not treat underlying inflammation. Thus, over-reliance on SABA may result in poor asthma control and negative health outcomes. ...Patients in NS wit …
BACKGROUND: Patients with asthma use short-acting beta-agonists (SABA) to relieve symptoms but SABA alone does not treat under …
SABA Reliance Questionnaire (SRQ): Identifying Patient Beliefs Underpinning Reliever Overreliance in Asthma.
Chan AHY, Katzer CB, Horne R, Haughney J, Correia de Sousa J, Williams S, Kaplan A. Chan AHY, et al. J Allergy Clin Immunol Pract. 2020 Nov-Dec;8(10):3482-3489.e1. doi: 10.1016/j.jaip.2020.07.014. Epub 2020 Jul 20. J Allergy Clin Immunol Pract. 2020. PMID: 32702517
OBJECTIVE: To develop and validate a brief questionnaire to elicit patients' perceptions of SABA (eg, belief that asthma is best managed by SABA alone) that could lead them to be overly reliant on SABA. METHODS: The 5-item SABA Reliance Questionnaire ( …
OBJECTIVE: To develop and validate a brief questionnaire to elicit patients' perceptions of SABA (eg, belief that asthma is best mana …
Clarifying SABA overuse: Translating Canadian Thoracic Society guidelines into clinical practice.
Ellis AK, Foran V, Kaplan A, Mitchell PD. Ellis AK, et al. Allergy Asthma Clin Immunol. 2022 Jun 11;18(1):48. doi: 10.1186/s13223-022-00690-2. Allergy Asthma Clin Immunol. 2022. PMID: 35690850 Free PMC article.
The CTS developed an algorithm as a guide for deciding for whom PRN budesonide/formoterol versus PRN SABA is appropriate as a reliever. While the CTS algorithm provides necessary and precise guidance, the somewhat complicated requirements for determining control and exacer …
The CTS developed an algorithm as a guide for deciding for whom PRN budesonide/formoterol versus PRN SABA is appropriate as a relieve …
Increasing evidence of the role of Helicobacter pylori SabA in the pathogenesis of gastroduodenal disease.
Yamaoka Y. Yamaoka Y. J Infect Dev Ctries. 2008 Jun 1;2(3):174-81. doi: 10.3855/jidc.259. J Infect Dev Ctries. 2008. PMID: 19738347 Free PMC article. Review.
However, when host inflammation increases, expression of sialyl-Lewis x increases, and H. pylori is likely to adhere to the gastric mucosa with SabA. Many of the genes encoding outer membrane proteins undergo phase variation such that not all strains will produce functiona …
However, when host inflammation increases, expression of sialyl-Lewis x increases, and H. pylori is likely to adhere to the gastric mucosa w …
11,683 results
You have reached the last available page of results. Please see the User Guide for more information.